Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care JournalsDavid J. Lederer, Jean‐Louis Vincent, Scott C. Bell et al.|Annals of the American Thoracic Society|2018Cited by 723
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Thomas Bengtsson et al.|The Lancet Respiratory Medicine|2021Cited by 434
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialLy‐Mee Yu, Mona Bafadhel, Jienchi Dorward et al.|The Lancet|2021Cited by 310
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trialSanjay Ramakrishnan, Mona Bafadhel, Richard Russell et al.|The Lancet Respiratory Medicine|2024Cited by 98
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysisJonathan Baker, Mona Bafadhel, Mahdi Mahdi et al.|The Lancet Respiratory Medicine|2022Cited by 58